Malignant pleural mesothelioma is a neoplasm characterized by an increasing incidence and poor prognosis. When surgical treatment cannot be performed, systemic chemotherapy remains the main therapeutic option. Here we report the case of a 41-year-old female patient with epithelioid malignant pleural mesothelioma who was treated with carboplatin and pemetrexed despite her critical condition. She showed an impressive response to this first-line chemotherapy and, after disease progression, to further chemotherapy with gemcitabine and vinorelbine. She is still alive, with unexpectedly long-lasting survival. Free full text available at www.tumorionline.it
VogelzangN.J., RusthovenJ.J., SymanowskiJ., DenhamC., KaukelE., RuffieP., GatzemeierU., BoyerM., EmriS., Mane-goldC., NiyikizaC., PaolettiP.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21: 2636–2644, 2003.
4.
CeresoliG.L., CastagnetoB., ZucaliP.A., FavarettoA., MencoboniM., GrossiF., CortinovisD., Del ConteG., CeribelliA., BearzA., SalaminaS., DeVincenzoF., CappuzzoF., MarangoloM., TorriV., SantoroA.: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer, 99: 51–56, 2008.
5.
ZucaliP.A., CeresoliG.L., GarassinoI., De VincenzoF., CavinaR., CampagnoliE., CappuzzoF., SalaminaS., Soto ParraH.J., SantoroA.: Gemcitabine and vinorelbine in pemetrexed pretreated patients with malignant pleural mesothelioma. Cancer, 112: 1555–1561, 2008.
6.
CurranD., SahmoudT., TherasseP., van MeerbeeckJ., PostmusP.E., GiacconeG.: Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol, 16: 145–152, 1998.
7.
HerndonJ.E., GreenM.R., ChahinianA.P., CorsonJ.M., SuzukiY., VogelzangN.J.: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113: 723–731, 1998.
8.
Ismail-KhanR., RobinsonL.A., WilliamsC.C.Jr., GarrettC.R., BeplerG., SimonG.R.: Malignant pleural mesothelioma: a comprehensive review. Cancer Control, 13: 255–263, 2006.
BorasioP., BerrutiA., BilléA., LausiP., LevraM.G., GiardinoR., ArdissoneF.: Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg, 33: 307–313, 2008.
11.
CeresoliG.L., LocatiL.D., FerreriA.J., CozzariniC., PassoniP., MelloniG., ZanniniP., BolognesiA., VillaE.: Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer, 34: 279–287, 2001.
12.
ByrneM.J., DavidsonJ.A., MuskA.W., DewarJ., van HazelG., BuckM., de KlerkN.H., RobinsonB.W.: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol, 17: 25–30, 1999.
13.
Van den BogaertD.P., PouwE.M., van WijheG., VernhoutR.M., SurmontV.F., HoogstedenH.C., van KlaverenR.J.: Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol, 1: 25–30, 2006.
14.
KarrisonT., KindlerH.L., GandaraD.R., LuC., GuterzT., NicholsK., ChenH., StadlerW.M., VokesE.E.: Final analysis of a multicenter, double blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients with malignant mesothelioma. J Clin Oncol, 25: 7526 (abstr), 2007.
15.
StebbingJ., PowlesT., McPhersonK., ShamashJ., WellsP., SheaffM.T., SlaterS., RuddR.M., FennellD., SteeleJ.P.: The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer, 63: 94–97, 2009.
16.
JackmanD.M., KindlerH.L., YeapB.Y., FidiasP., SalgiaR., LuccaJ., MorseL.K., OstlerP.A., JohnsonB.E., JänneP.A.: Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer, 113: 808–814, 2008.
17.
AliY., LinY., GhariboM.M., GounderM.K., SteinM.N., LagattutaT.F., EgorinM.J., RubinE.H., PoplinE.A.: Phase I and pharmacokinetic study of imatinib mesylate (Gleevec®) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res, 13: 5876–5882, 2007.
18.
PietrasK., RubinK., SjoblomT., BuchdungerE., SjoquistM., HeldinC.H., OstmanA.: Inhibition of PDGR receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res, 62: 5476–5484, 2002.
